Recce Pharmaceuticals (ASX: RCE) (FSE: R9Q) is developing a new class of synthetic anti-infectives designed to address the urgent global health threat of antibiotic-resistant superbugs and sepsis.
✅ Proprietary new class of anti-infectives against bacteria and viruses
✅ Designed to work against antibiotic-resistant bacteria - with repeated use!
✅ Multiple Phase I and Phase II clinical programs, addressing unmet medical needs
Learn more about the company's strategy in our DGWA CEO interview with Recce's CEO James Graham: